Abeona Therapeutics Shares Owned By Institutions vs. Revenue
| ABEO Stock | USD 5.98 0.19 3.28% |
For Abeona Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Abeona Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Abeona Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Abeona Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Abeona Therapeutics over time as well as its relative position and ranking within its peers.
Abeona |
Abeona Therapeutics' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.38) | Return On Equity (1.27) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Abeona Therapeutics Revenue vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Abeona Therapeutics's current stock value. Our valuation model uses many indicators to compare Abeona Therapeutics value to that of its competitors to determine the firm's financial worth. Abeona Therapeutics is rated second in shares owned by institutions category among its peers. It is rated third in revenue category among its peers totaling about 45,136 of Revenue per Shares Owned By Institutions. At this time, Abeona Therapeutics' Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Abeona Therapeutics' earnings, one of the primary drivers of an investment's value.Abeona Revenue vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Abeona Therapeutics |
| = | 77.54 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Abeona Therapeutics |
| = | 3.5 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Abeona Revenue vs Competition
Abeona Therapeutics is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 149.31 Million. Abeona Therapeutics holds roughly 3.5 Million in revenue claiming about 2.34% of equities under Health Care industry.
Abeona Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Abeona Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Abeona Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Abeona Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Abeona Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -66 K | -69.3 K | |
| Operating Income | -47.1 M | -44.8 M | |
| Income Before Tax | -54.2 M | -51.5 M | |
| Net Loss | -54.2 M | -51.5 M | |
| Total Other Income Expense Net | -7.1 M | -6.7 M | |
| Income Tax Expense | 3 M | 3.2 M | |
| Net Loss | -54.2 M | -56.9 M | |
| Non Operating Income Net Other | 1.7 M | 1.8 M | |
| Net Loss | -39.1 M | -41.1 M | |
| Interest Income | 2.1 M | 1.2 M | |
| Net Interest Income | 1.7 M | 1.8 M | |
| Change To Netincome | 38 M | 39.9 M | |
| Net Loss | (2.53) | (2.66) | |
| Income Quality | 0.68 | 0.95 | |
| Net Income Per E B T | 0.72 | 0.56 |
Abeona Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Abeona Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Abeona Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Abeona Therapeutics' important profitability drivers and their relationship over time.
Use Abeona Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.Abeona Therapeutics Pair Trading
Abeona Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Abeona Therapeutics position
In addition to having Abeona Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Synthetics Thematic Idea Now
Synthetics
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
To fully project Abeona Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Abeona Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Abeona Therapeutics' income statement, its balance sheet, and the statement of cash flows.